BioSpace News Archive

Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) dosed prescription drug based on a “water‑free” semifluorinated alkane eyedrop technology, is now available in the U.S. – and includes a 100% Money‑Back Guarantee program.

United Digestive has introduced a personalized education program powered by Boston Scientific.

Praxis Precision Medicines , Inc. today announced the pricing of its underwritten public offering of 3,168,275 shares of its common stock at a public offering price per share of $35.50 and, in lieu of shares of common stock.

Spectral AI, Inc. announces the enrollment of the first patient in the pivotal study to validate DeepView AI ® using its proprietary imaging technology for burn size and healing assessment.

TransCode Therapeutics, Inc. today announced that its Board of Directors has approved a 1-for-40 reverse stock split, to be effective at 12:01 a.m. Eastern Standard Time Tuesday, January 16, 2024.

VECT-HORUS today announced the appointment Pr. Xavier Declèves to its scientific advisory board (SAB).

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it will regain global commercialization rights to FAMPYRA ® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement between the companies, effective January 1, 2025.

ELIQUENT Life Sciences today announced the appointment of Steve Purtell as its new chief financial officer (CFO).

Xcell Biosciences, Inc. today announced a collaboration with ElevateBio, LLC (ElevateBio), through which the companies aim to explore novel approaches to improving therapeutic potency of cell and gene therapies.

Sapio Sciences today announced that its unified platform for research and clinical informatics has been validated to comply with “good practice” quality guidelines and regulations.